Vaksin Japanese Encephalitis: Manfaat dan Komplikasi
DOI:
https://doi.org/10.55175/cdk.v45i12.681Keywords:
Efektivitas, Japanese encephalitis, pencegahan, vaksinAbstract
Japanese encephalitis (JE) adalah infeksi virus sistem susunan saraf pusat yang ditularkan oleh nyamuk Culex. Infeksi ini lebih sering mengenai anak di bawah usia 15 tahun. Seluruh wilayah di Indonesia merupakan daerah berisiko, terbanyak di Bali, Kalimantan Barat, dan Sulawesi Utara. Penyakit ini dapat menyebabkan kematian dan kecacatan. Vaksinasi JE merupakan strategi yang baik untuk mengurangi angka kematian serta kecacatan pada anak-anak. Di Indonesia, vaksin JE sudah direkomendasikan oleh Ikatan Dokter Anak Indonesia untuk usia lebih dari 1 tahun. Vaksin yang beredar di Indonesia merupakan vaksin hidup rekombinan yang dilemahkan dengan efektivitas hampir sama dengan jenis vaksin lain.
Japanese encephalitis (JE) is a viral central nervous system infection transmitted by Culex mosquitoes. This infection frequently affects children under 15 year-old. Indonesia is a vulnerable area, mostly in Bali, West Borneo, and North Sulawesi. Mortality and morbidity is a serious complication. Vaccination is a good strategy to reduce mortality and morbidity in children. JE vaccine is recommended by Indonesian Pediatric Society for more than 1 year-old. Vaccine in Indonesia is live attenuated chimeric vaccine and the level of effectivity is similar to the other vaccine.
Downloads
References
Wang H, Liang G. Epidemiology of Japanese encephalitis: Past, present, and future prospects. Ther Clin Risk Manag. 2015;11:435-48.
Malhotra S, Sharma S, Hans C. Japanese encephalitis and its epidemiology. J Infect Dis Ther. 2015;3:5.
Yoshida M, Igarashi A, Suwendra P, Inada K, Maha MS, Kari K, et al. The first report on human cases serologically diagnosed as Japanese encephalitis in Indonesia. Southeast Asian J Trop Med Public Health. 1999;30(4):698–706
Kari K, Liu W, Gautama K, Mammen MP Jr, Clemens JD, Nisalak A, et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 2006;4:8
Putra PJ, Kari IK. Manifestasi klinis dan faktor-faktor yang berhubungan dengan Japanese Encephalitis di RSUP Sanglah Denpasar. Sari Pediatri. 2007;8:15-20.
Kementerian Kesehatan Republik Indonesia. Japanese enchepalitis berkorelasi dengan banyaknya area persawahan, peternakan babi dan burung rawa. Kemenkes RI [Internet]. 2017 [cited 2018 May 1]. Available from: http://www.depkes.go.id/article/view/17040400003/japanese-encephalitis-disease-correlates-with-numbersof-rice-field-area-pig-farms-and-wading-birds.html.
Pusponegoro H, Sitaresmi MN, Hartoyo E. Japanese ensefalitis. In: Ranuh IGNG, Hadinegoro SRS, Kartasasmita CB, Ismoedijanto, Soedjatmiko, Gunardi H, et al, editors. Pedoman Imunisasi di Indonesia. 6th ed. Jakarta: IDAI; 2017. p. 385-91.
Hills SL, Rabe IB, Fischer M. Infectious diseases related to travel. In: Brunette GW, editor. CDC Health Information for International Travel 2016. USA: Oxford University Press; 2016.
Kakoti G, Dutta P, Das BR, Borah J, Mahanta J. Clinical profile and outcome of Japanese encephalitis in children admitted with acute encephalitis syndrome. BioMed Res Int. 2013;2013:152656.
Directorate of National Vector-Borne Disease Control Programme. Guidelines for surveillance of acute encephalitis syndrome (with special reference to Japanese encephalitits). India: Directorate General of Health Services, Ministry of Health and Family Welfare; 2006.
Batchelor P, Petersen K. Japanese encephalitis: A review of clinical guidelines and vaccine availability in Asia. Trop Dis. Travel Med Vaccines. 2015;1:11.
World Health Organization. International travel and health: Japanese encephalitis. WHO [Internet]. 2018. [cited 2018 May 1]. Available from: http://www.who.int/ith/vaccines/japanese_encephalitis/en/.
Chen H, Chang J, Tang R. Current recommendations for the Japanese encephalitis vaccine. J Chinese Med Assoc. 2015;78:271-5.
MIMS Indonesia. Vaccine, Japanese encephalitis. MIMS [Internet]. 2018 [cited 2018 May 1]. Available from: http://www.mims.com/indonesia/drug/info/vaccine,%20japanese%20encephalitis.
Ikatan Dokter Anak Indonesia. Jadwal imunisasi 2017. IDAI [Internet]. 2017 [cited 2018 May 1]. Available from: http://www.idai.or.id/artikel/klinik/imunisasi/jadwalimunisasi-2017.
Australian Government Department of Health. Japanese encephalitis. In: Australian Immunisation Handbook. Australian Technical Advisory Group on Immunisation [Internet]. 2015 [cited 2018 May 1]. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/content/Handbook10-home~handbook10part4~handbook10-4-8.
Chotpitayasunondh T, Pruekprasert P, Puthanakit T, Pancharoen C, Tangsathapornpong A, Oberdorfer P, et al. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine. 2017;35:299-304.
Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, et al. Single-dose, live-attenuated Japanese encephalitis vaccinein children aged 12–18 months: Randomized, controlled phase 3immunogenicity and safety trial. Hum Vaccin Immunother. 2012;8:929–37.
Wang Y, Dong D, Cheng G, Zuo S, Liu D, Du X. Post-marketing surveillance oflive-attenuated Japanese encephalitis vaccine safety in China. Vaccine 2014;32:5875–9.
Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Muller Z. Safetyprofile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccineIXIARO((R)). Vaccine 2011;29:8669–76.
Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, et al. A randomized study of the immunogenicity andsafety of Japanese encephalitis chimeric virusvaccine (JE-CV) in comparison with SA14–14–2 vaccine in children in the Republic of Korea. Human Vaccines Immunotherapeutics. 2014;10:9.
Wijesinghe PR, Abeysinghe N, Yoksan S, Yaou Y, Zhou, B, Zhang L, et al. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine. Vaccine 2016;34:5923-28.
Therapeutic Goods Administration. Australian public assessment report for Japanese encephalitis Chimeric virus. AusPAR. 2010
Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30:2510-5.
Hedge NR, Gore MM. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Human Vaccines Immunotherapeutics. 2017;13:1320-37.
Wang H, Li Y, Liang X, Liang G. Japanese encephalitis in mainland China. Jpn J Infect Dis. 2009;62:331-6. PMID:19762980
Zhang L, Luan RS, Jiang F, Rui LP, Liu M, Li YX, et al. Epidemiological characteristics of Japanese encephalitis in Guizhou Province, China, 1971–2009. Biomed Environ Sci. 2012;25:297-304.PMID:22840580
Ranjan P, Gore M, Selvaraju S, Kushwaha KP, Srivastava DK, Murhekar M. Changes in acute encephalitis syndrome incidence afterintroduction of Japanese encephalitis vaccine in a region in India. J Infect 2014;69:200-2; PMID:24657663; https://doi.org/10.1016/j.jinf.2014.03.013
Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, et al. Vaccine preventable diseases surveillance programof Japan. Jpn J Infect Dis. 2008;61:333-8. PMID:18806337
Satou K, Nishiura H. Evidence of the partial effects of inactivated Japanese encephalitis vaccination: Analysis of previous outbreaks in Japan from 1953 to 1960. Ann Epidemiol. 2007;17:271-7; PMID:17300956. https://doi.org/10.1016/j.annepidem.2006.10.003
Impoinvil DE, Ooi MH, Diggle PJ, Caminade C, Cardosa MJ, MorseAP, et al. The effect of vaccination coverage andclimate on Japanese encephalitis in Sarawak, Malaysia. PLoS Negl Trop Dis. 2013;7:2334; PMID:23951373;https://doi.org/10.1371/journal.pntd.0002334
Dumre SP, Shakya G, Na-Bangchang K, Eursitthichai V, RudiGrams H, Upreti SR, et al. Dengue virus and Japanese encephalitis virus epidemiological shifts in Nepal: A case of opposing trends. Am J Trop Med Hyg. 2013;88:677-80; PMID:23419366; https://doi.org/10.4269/ajtmh.12-0436
Upreti SR, Janusz KB, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, et al. Estimationof the impact of a Japanese encephalitis immunizationprogram with live, attenuated SA 14-14-2 vaccine in Nepal. Am J Trop Med Hyg. 2013;88:464-8. PMID:23358643; https://doi.org/10.4269/ajtmh.12-0196
Centers for Disease Control and Prevention. Inactivated Japaneseencephalitis vaccine. Recommendations of the Advisory Committeeon Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42(RR-1):1-15
De Alwis KN, Abeysinghe MR, Wickramesinghe AR, Wijesinghe PR. A cohort event monitoring to determine the adverse events following administration of mouse brain derived, inactivated Japanese encephalitis vaccine in an endemic district in Sri Lanka. Vaccine1336 N. R. HEGDE AND M. M. GORE2014; 32:924-0;PMID:24406391; https://doi.org/10.1016/j.vaccine.2013.12.047
Okuno T, Tseng PT, Hsu ST, Huang CT, Kuo CC. Japanese encephalitis surveillance in China (Province of Taiwan) during 1968–1971.II. Age-specific incidence in connection with Japanese encephalitis vaccination program. Jpn J Med Sci Biol. 1975; 28:255-67;PMID:180320; https://doi.org/10.7883/yoken1952.28.255
Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, et al. The incidence of Japanese encephalitis in Taiwan – a population-based study. PLoS Negl Trop Dis. 2014; 8:e3030;PMID:25058573;https://doi.org/10.1371/journal.pntd.0003030
Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, et al. Review on flavivirusvaccine development. Proc. Meeting jointly organized by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, Thailand. Vaccine 2005;23:2689-95; PMID:15841565; https://doi.org/10.1016/j.vaccine.2004.11.040
Wierzba TF, Ghimire P, Malla S, Banerjee MK, Shrestha S, KhanalB, et al. Laboratory-based Japanese encephalitis surveillance in Nepal and the implications for a national immunization strategy. Am J Trop Hyg. 2008; 78:1002-6
Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand.Southeast Asian J Trop Med Public Health 1997; 28:143-8.PMID:9322297
Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Org. 2003; 81:334-42.PMID:12856051
Touch S, Suraratdecha C, Samnang C, Heng S, Gazley L, Huch C, et al. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine 2010;28:4593-9; PMID:20470803; https://doi.org/10.1016/j.vaccine.2010.04.086
Liu W, Clemens JD, Kari K, Xu ZY. Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine 2008;26:4456-60; PMID:18602436; https://doi.org/10.1016/j.vaccine.2008.06.050
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
